Why GA-map®?
Reference values
50+ publications
70+ clinical trials
Bioinformatic services
Microbiome analysis services
The GA-map® technology offers a standardized platform that features an end-to-end workflow for targeted microbiota analysis. We provide services tailored for all types of clinical research.
GA-map® Dysbiosis Test is a microbiota test for detection and characterization of dysbiosis in human fecal samples. The test is the first CE-IVD approved assay providing microbiota profiling with an intrinsic healthy reference.
GA-map® Discovery is a Research Use Only, comprehensive, end-to-end microbiota profiling service for clinical and industry research. The service provides deep insight into gut and oral microbiota, based on analysis of over 170 clinically important bacteria.
Looking for a time efficient microbiota analysis to incorporate in your study? Contact us today to discuss your project.
Your research project timeline
Step 1: Study design consultancy
Our experienced team will help you decide the perfect study set up, sample collection solution, and chose the right analyses.
Step 2: Sample collection and shipment
We run microbiota analyses on fecal samples, saliva samples, or pre-extracted gDNA. We assist you with solutions for easy sample collection.
Step 3: Sample analysis
We run the study samples according to agreed protocol and timeline. We pride ourselves on the complete sample workflow and short turnaround.
Step 4: Data analysis
GA-map® results are easy to interpret and require no data storage capacity. Bioinformatic analysis is performed upon request.
GA-map® Dysbiosis Test features
Dysbiosis index
Reference population
Diversity
Bacterial abundance
GA-map® Discovery features
Comprehensive gut panel
Oral bacteria markers
In-depth profiling
Opportunistic pathogens
Benefits of the GA-map® technology
 | Speed and throughputResults in 1-2 days for a 96-well plate | Cost efficiencyLow cost per sample | SpecificitySpecies level resolution | ReproducibilityStandardized, highly accurate and reproducible results | Pre-determined approachA panel targeting only the relevant bacteria | MultiplexityDetects multiple bacteria targets simultaneously |
|---|---|---|---|---|---|---|
| qPCR | ||||||
| 16s rRNA Sequencing | ||||||
| Shotgun metagenomics | ||||||
| GA-map® |
Validated parameters in GA-map® Dysbiosis Test
Reference values
Relative abundance compared to healthy normal
No data processing steps
Patented algorithm providing ready-to-use results
Dysbiosis Index
Validated gut microbiota dysbiosis indicator
CE-IVD approved
Meets high safety, health, and environmental requirements
Publications
An increasing number of researchers have discovered the efficiency and simplicity of the GA-map® Dysbiosis Test in gut microbiota analysis.
Merging the rapidness, preciseness, and robustness of RT-PCR approaches with the comprehensiveness of next-generation sequencing, the GA-map® technology drastically reduces the time from analysis to publication.
The GA-map® technology has until now been applied in clinical research in the fields of gastroenterology (IBS and IBD) and metabolic disorders (Diabetes and Obesity).
We used GA-map® in our clinical research within IBS. We have great experience with GA-map® as a tool to select, monitor and follow-up patients.
Professor Magdy El-Salhy
Stord Hospital, Helse Bergen and the University of Bergen, Norway
There is still so much to learn about the microbiome, we are only just beginning to discover its importance, and the GA-map® Dysbiosis Test will help us do just that.
Emeritus Professor Peter Malfertheiner
Senior Professor at the Ludwig Maximillian University, University Clinic in Munich, Germany
Industry partners
Academic Network
